AG2R LA Mondiale Gestion D Actifs Invests $8.56 Million in Abbott Laboratories $ABT

Key Points

• AG2R LA Mondiale Gestion D Actifs acquired 64,094 shares of Abbott Laboratories in Q1, valued at approximately $8.56 million, highlighting increased institutional interest in the stock.
• Abbott Laboratories reported $1.26 EPS for its last quarterly earnings, meeting expectations, with revenues of $11.14 billion, marking a 7.4% year-over-year increase.
• Several analysts have upgraded Abbott Laboratories' stock ratings, with target prices now ranging from $140 to $145, reflecting optimistic growth forecasts for the company.

AG2R LA Mondiale Gestion D Actifs acquired a new position in shares of Abbott Laboratories (NYSE:ABT - Free Report) in the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 64,094 shares of the healthcare product maker's stock, valued at approximately $8,562,000.

Other large investors have also modified their holdings of the company. Howe & Rusling Inc. grew its stake in shares of Abbott Laboratories by 6.4% during the first quarter. Howe & Rusling Inc. now owns 5,478 shares of the healthcare product maker's stock valued at $727,000 after acquiring an additional 329 shares in the last quarter. Maple Capital Management Inc. boosted its stake in Abbott Laboratories by 0.3% during the first quarter. Maple Capital Management Inc. now owns 169,957 shares of the healthcare product maker's stock worth $22,545,000 after buying an additional 584 shares in the last quarter. eCIO Inc. bought a new stake in shares of Abbott Laboratories during the first quarter worth $155,000. Cim LLC increased its position in shares of Abbott Laboratories by 4.2% in the 1st quarter. Cim LLC now owns 17,686 shares of the healthcare product maker's stock valued at $2,346,000 after buying an additional 719 shares in the last quarter. Finally, CBIZ Investment Advisory Services LLC grew its stake in shares of Abbott Laboratories by 49.8% in the first quarter. CBIZ Investment Advisory Services LLC now owns 331 shares of the healthcare product maker's stock valued at $44,000 after buying an additional 110 shares in the last quarter. 75.18% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Abbott Laboratories

In other Abbott Laboratories news, CFO Philip P. Boudreau sold 5,550 shares of Abbott Laboratories stock in a transaction on Friday, August 8th. The shares were sold at an average price of $134.55, for a total transaction of $746,752.50. Following the sale, the chief financial officer owned 51,003 shares in the company, valued at $6,862,453.65. The trade was a 9.81% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 0.46% of the stock is owned by company insiders.

Analyst Ratings Changes

A number of research firms have weighed in on ABT. William Blair raised shares of Abbott Laboratories to a "strong-buy" rating in a research report on Thursday, July 17th. Evercore ISI lifted their target price on shares of Abbott Laboratories from $140.00 to $145.00 and gave the company an "outperform" rating in a research report on Tuesday, July 8th. Jefferies Financial Group upgraded Abbott Laboratories from a "hold" rating to a "buy" rating and boosted their price target for the company from $143.00 to $145.00 in a report on Friday, July 18th. Raymond James Financial dropped their price target on shares of Abbott Laboratories from $142.00 to $141.00 and set an "outperform" rating on the stock in a research note on Friday, July 18th. Finally, Royal Bank Of Canada upped their price target on Abbott Laboratories from $145.00 to $147.00 and gave the stock an "outperform" rating in a research note on Tuesday, July 15th. Two investment analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $144.47.

Abbott Laboratories Price Performance

Abbott Laboratories stock traded up $1.43 during midday trading on Tuesday, reaching $132.76. The company's stock had a trading volume of 5,400,229 shares, compared to its average volume of 6,654,733. The stock's 50 day simple moving average is $130.36 and its 200 day simple moving average is $131.21. The firm has a market capitalization of $231.06 billion, a PE ratio of 16.64, a P/E/G ratio of 2.54 and a beta of 0.69. Abbott Laboratories has a fifty-two week low of $110.86 and a fifty-two week high of $141.23. The company has a debt-to-equity ratio of 0.25, a quick ratio of 1.30 and a current ratio of 1.82.

Abbott Laboratories (NYSE:ABT - Get Free Report) last released its quarterly earnings data on Thursday, July 17th. The healthcare product maker reported $1.26 earnings per share (EPS) for the quarter, hitting the consensus estimate of $1.26. The company had revenue of $11.14 billion during the quarter, compared to analyst estimates of $11.01 billion. Abbott Laboratories had a net margin of 32.43% and a return on equity of 18.32%. The business's quarterly revenue was up 7.4% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.14 earnings per share. Abbott Laboratories has set its FY 2025 guidance at 5.100-5.200 EPS. Q3 2025 guidance at 1.280-1.320 EPS. On average, equities research analysts forecast that Abbott Laboratories will post 5.14 earnings per share for the current year.

Abbott Laboratories Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.